Navigation Links
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Date:9/26/2007

rug is ground-breaking. Going forward, we will leverage the ability to use PEGylation technology to manage penetration of the blood-brain barrier with additional, innovative CNS product opportunities."

Phase 1 Clinical Study Design and Results

This single-dose, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of NKTR-118 in healthy male subjects. The trial measured the morphine-induced delay in GI transit time, a peripheral effect, using the lactulose hydrogen GI motility test. Pupillometry, a measurement of the diameter of the pupil of the eye, was used to monitor antagonism of morphine-induced pupil constriction, a central nervous system (CNS) effect. Escalating single oral doses of NKTR-118 up to 1,000 mg were studied. A total of 48 subjects received active NKTR-118 as compared to placebo.

Single oral doses of NKTR-118 antagonized morphine-induced delay in GI transit time demonstrating the potential of the drug to relieve constipation. Further, no diminution of morphine-induced construction of the pupil, a CNS effect, was observed at single oral doses of NKTR-118 of 125 mg or less. NKTR-118 was well-tolerated at single doses up to 1,000 mg. Further, NKTR-118 was rapidly absorbed with dose-proportional pharmacokinetics over the 8-1,000 mg dose range.

Preclinical Results for NKTR-118

Preclinical studies conducted in animals investigated the permeation rate of NKTR-118 administered as compared to naloxone, antipyrine (a high brain permeation standard) and atenolol (a low brain permeation standard with no appreciable blood brain barrier penetration). NKTR-118 showed brain permeation similar to atenolol. PEGylation of naloxol greatly reduced, by 15-fold, the permeation of the drug into the brain, as compared to naloxone.

Oral NKTR-118, administered at a dose of 30 mg/kg, demonstrated the ability to improve GI transit time in an animal model of mor
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of ... liver diseases and cholesterol gallstones, today announced that ... Vice President of Clinical Operations. Mr. ... clinical operations, development and regulatory affairs.  From 2005 ...
(Date:4/1/2015)... Minn. , April 1, 2015  EnteroMedics ... devices using neuroblocking technology to treat obesity, metabolic ... the Company has entered into a partnership with ... access to vBloc® Therapy, delivered via the Maestro® ... System is approved for adults with a BMI ...
(Date:3/31/2015)... and ORANGEBURG, N.Y., March 31, 2015 Uroplasty, ... announced the completion of their merger. The merger ... of the all-stock combination creates a new medical ... April 1, 2015, Cogentix Medical, Inc. will trade ... Medical will have its U.S. headquarters in ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy 2EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy 3EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy 4Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
... show evidence of additional protection,against infection with ... 17, 2007 /PRNewswire-FirstCall/ -- The,GlaxoSmithKline cervical cancer ... preventing precancerous,lesions due to cancer-causing human papillomavirus ... years in an extended follow-up trial, according ...
... Alnylam,Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi ... for Cancer,Research (AACR) 2007 Annual Meeting that ... ALN-VSP01, for the,treatment of liver cancer and ... program. ALN-VSP01 is an RNAi therapeutic that ...
Cached Medicine Technology:Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 2Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 3Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 4Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 5Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5
(Date:4/1/2015)... 01, 2015 Franklin University, one of ... announce the establishment of the Greta J. Russell Medical ... possible through the generous gift of $100,000 from Medical ... behalf of Medical Mutual to University representatives, Dr. ... of Advancement & Strategic Relations. , “We are ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Pricing Healthcare ... last several months, bring coverage to a third of all ... states of Massachusetts, Kansas, and Iowa, and the first dedicated eye ... center in Dallas, TX was also added. , In addition, the ... to and general interest in the platform continue to grow across ...
(Date:4/1/2015)... Patients with inoperable mesothelioma may soon ... to the FDA’s approval of CRS-207’s orphan drug application ... on the Surviving Mesothelioma website. , CRS-207 ... of the bacteria that causes the food-borne illness Listeriosis. ... funding and other incentives to support continued testing and ...
(Date:4/1/2015)... 2015 Phybridge Inc., a provider ... today its strategic partnership with SaskTel in a ... the businesses of Saskatchewan. SaskTels’ Integrated Business Communications ... that offers users a hosted IP unified communications ... The objective of IBC is to offer an ...
(Date:4/1/2015)... 01, 2015 The dearth of ... are set to retire in the next five ... demand for laboratory automation. The application of advanced ... it ensures timely progress and efficiency with minimal ... lab automation in high-throughput screening, combinatorial chemistry, automated ...
Breaking Medicine News(10 mins):Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 2Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 3Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 3Health News:Orphan Drug Approval May Mean New Treatment Option for Mesothelioma, According to Surviving Mesothelioma 2Health News:Phybridge and SaskTel Team Up to Eliminate Network Barriers for IP Telephony and Unified Communications Migration 2Health News:Phybridge and SaskTel Team Up to Eliminate Network Barriers for IP Telephony and Unified Communications Migration 3Health News:Laboratory Accessories Market Worth $504.7 Million by 2020 – New Research Report by MarketsandMarkets 2Health News:Laboratory Accessories Market Worth $504.7 Million by 2020 – New Research Report by MarketsandMarkets 3
... LUGANO, Switzerland, September 9 As part ... been appointed as new,CEO in the American subsidiary, Helsinn ... Officer of the recently acquired,Helsinn Therapeutics, and has held ... Development and in Research. , ...
... ... Patient Education Reference Center™ Available online at www.ebscohost.com/flu . The Latest Evidence-based ... ... -- Concerns about Pandemic H1N1 and the upcoming flu season have people on alert ...
... ... Year , ... GA (PRWEB) September 9, 2009 -- Kennesaw, Georgia-based Cobb Pediatric Therapy Services, a pediatric ... systems across the U.S., has been named one of the country,s fastest growing private ...
... ... Inc. today announced the completion of over a dozen more HL7 ... in the medical industry. pMDsoft,s industry-leading interface engine has allowed ... data entry and increasing the accuracy of their claims. The ...
... , - Choosing a More Appropriate ... to Improvement , The first results of ... presented today at the 6th congress,of the European Federation of Chapters ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 ) , ...
... owners and employees are among those who stand to ... current health reform proposals under consideration by Congress according ... to extend health care coverage to everyone and repair ... costs, high broker fees, underwriting, and a lack of ...
Cached Medicine News:Health News:New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc. 2Health News:EBSCO Publishing Makes Evidence-Based Flu Resources Freely Available 2Health News:EBSCO Publishing Makes Evidence-Based Flu Resources Freely Available 3Health News:Cobb Pediatric Therapy Services Is Recognized by Inc. Magazine as One of the Fastest Growing Private Companies 2Health News:pMDsoft Announces Interfaces with Additional EMR, EHR, Practice Management, Hospital and Billing Systems 2Health News:pMDsoft Announces Interfaces with Additional EMR, EHR, Practice Management, Hospital and Billing Systems 3Health News:pMDsoft Announces Interfaces with Additional EMR, EHR, Practice Management, Hospital and Billing Systems 4Health News:pMDsoft Announces Interfaces with Additional EMR, EHR, Practice Management, Hospital and Billing Systems 5Health News:First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 2Health News:First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 3Health News:Small businesses would see lower costs, more comprehensive coverage from health reform 2Health News:Small businesses would see lower costs, more comprehensive coverage from health reform 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: